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low W:H-R (odds ratio 1.6). These patterns were even more
obvious in diabetic patients. Similar results could be shown by
combining BMI and waist circumference only. CONCLUSIONS:
BMI in addition to W:H-R or waist circumference is a better
and more precise predictor of obesity-related complications, and
should where possible be preferentially used. Longitudinal
obesity-related outcome data are needed.
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OBJECTIVE: To examine the cost-effectiveness of sibutramine
plus a structured weight management program (WMP) versus
only structured WMP. METHODS: Cost-effectiveness analysis
based on a randomized controlled trial conducted within a
managed care organization. The target population was obese or
overweight persons. The economic time horizon was two years
(pre and post study enrollment). Perspective was from that of a
managed care organization. The treatment arms consisted of
either sibutramine plus structured WMP or only WMP. The
primary outcomes were change in weight and percent change in
weight over 12 months, and change in obesity-related and total
medical costs 12 months prior to and 12 months after enroll-
ment. Non-parametric bootstrap was used to generate 95% con-
ﬁdence intervals for incremental cost-effectiveness ratios.
RESULTS: A total of 501 subjects were enrolled in the study,
281 receiving sibutramine plus structured WMP and 220 receiv-
ing only structured WMP. The mean (SD) weight loss was sig-
niﬁcantly greater in the sibutramine (13.7 (15.5) lbs) group than
the non-drug group (5.0 (13.2) lbs) (p < 0.001). Obesity-related
total cost between groups were different (p < 0.001), with a
median of $408 for sibutramine compared to $58 for the non-
drug group. The ICER for sibutramine was $44 (95% CI: $42
to $46) per additional pound of weight loss. Sensitivity analysis
suggested that changes in physician costs a negligible effect on
the results. If the cost of sibutramine was excluded, there was no
difference between the groups with respect to obesity-related
costs. A limitation of this study is that costs were estimated using
national fees schedules for hospital and physician visits and
average wholesale price for medications. CONCLUSION:
Patients enrolled in a weight management program receiving
sibutramine had greater weight loss and decrease in BMI at
greater cost than did patients enrolled in the same program who
did not receive sibutramine.
POB6
COSTS OF OBESITY IN THE UNITED STATES AND EUROPE:
A REVIEW OF THE LITERATURE
Budhiarso I, Derleth A, Martin ML
Health Research Associates, Mountlake Terrace, WA, USA
OBJECTIVE: To provide a broad picture of the costs of obesity
using data from the US and major European countries.
METHOD: Literature (2000–2004) was searched via Medline
using cost keywords: cost, cost-effectiveness, cost-beneﬁt, cost-
efﬁciency. Selected citations were reviewed by title and abstract,
followed by retrieval of relevant articles, review and synthesis of
cost information. RESULT: Direct medical expenditures for
obesity in the US were estimated to be between $70–$94 billion
and $331 billion—with all obesity associated comorbidities
included. This represented approximately 5.7%–9.4% of the
adult direct health spending. Cardiovascular disease and diabetes
constituted approximately 70% of the obesity-related cost. Indi-
rect costs associated with obesity were estimated to be at least
$48 billion. The expected mean costs for persons with BMI =
30–34 and BMI = 35–39 were 12% and 19% higher (respec-
tively) than persons with BMI < 25. Women spent more than
men for obesity care. In the US, Wyoming showed the lowest
expenditure for obesity ($87 million), and California the highest
($7.7 billion). Direct costs of obesity in Europe were estimated
between 1.5% and 4% of total health expenditures, with the UK,
Germany and France all showing similar expenditures (1.5%).
Expenses associated with comorbid hypertension, coronary heart
disease and diabetes were the main drivers of cost in the UK
(80.5%). Indirect costs in the UK were estimated at £2.1 billion,
of which £1.3 billion (61%) was due to work loss. Drug inter-
ventions using Orlistat, Sibutramine and Metformin were all
cost-effective with the cost per QALY gained ranging between
$8,327 to $19,968 (£4,780 to £45,881). CONCLUSION: The
costs attributable to obesity in both the US and Europe repre-
sented a signiﬁcant portion of the national health expenditure
for those countries reviewed, with comorbid cardiovascular
disease and diabetes constituting the major components of
obsesity associated health care costs.
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OBJECTIVES: To Estimate the health care costs and clinical out-
comes of various body mass index (BMI) levels over a lifetime.
METHODS: A Markov model was developed to perform cost-
effectiveness/utility analyses to evaluate obesity treatments
including lifestyle, pharmacological and surgical interventions.
User-deﬁned cohorts of obese adults can be followed over a life-
time assessing changes in costs and life expectancy. Baseline 
risk factors include age, gender, race and BMI. First and second
order Monte Carlo simulation techniques were utilized. To
compare the outcomes of three distinct BMI groups a 20 year-
old Caucasian male with varying baseline BMI (25, 35 and 45
kg.m-2) was chosen and it was assumed that no medical inter-
vention was undertaken. The perspective was third-party reim-
bursement in a US setting. Mortality was adjusted for age,
gender, race and BMI by Cox regression and applied to US life
tables. Costs and utility values were adjusted for age, gender and
BMI. US costs were derived from published resources and
inﬂated to year 2004 ﬁgures. Reported outcomes included direct
medical costs, life expectancy (LE) and quality-adjusted life
expectancy (QALE) all of which were discounted at 3% accord-
ing to US guidelines. RESULTS: Mean lifetime costs were
$85,393 (±1545), $97,156 (±1836) and $97,542 (±2937) for
BMI levels of 25, 35 and 45kg.m-2 respectively. Undiscounted
LEs were 54.43(±1.47), 51.48 (±1.37) and 42.04 (±1.69) years
respectively. Lifetime costs associated with a BMI of 45kg.m-2
from age 20 were approximately 14% higher than costs associ-
ated with BMI 25kg.m-2. Undiscounted life expectancy was
reduced by 12.39 years and discounted QALE was reduced by
3.52 years for BMI 45kg.m-2 versus 25kg.m-2. CONCLU-
SIONS: Raised BMI is associated with substantially greater
direct medical costs and diminished LE and QALE. This model
will allow health economic evaluations of the outcomes of
various anti-obesity interventions.
